Responders Vs. Non‐Responders or How to Predict the Response to GLP ‐1 or GLP ‐1/ GIP Receptor Agonist Therapy
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 10950-10960
DOI: 10.1111/dom.71226 ↗Abstract
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual GLP‐1/GIP receptor agonists have transformed the pharmacological management of type 2 diabetes (T2D) and obesity, yet substantial interindividual variability in treatment response remains a defining clinical challenge. Methods Narrative review. PubMed was searched to 25 May 2026 (English language, human studies, 2005–2026) for biological, genetic, metabolic, hormonal, behavioural and psychosocial predictors of differential response. Evidence is organised across three clinically distinct contexts: glycaemic control in T2D; weight loss in people with overweight or obesity without T2D; and dual metabolic benefit in those with both conditions. Results Response heterogeneity is most pronounced in obesity without diabetes, where non‐response—commonly defined as less than 5% total body weight loss—affects approximately 10% of participants in controlled trials, with real‐world cohorts suggesting a higher frequency in routine practice; glycaemic non‐response in T2D is less common but clinically significant. Across all three contexts, early on‐treatment response is the most readily actionable predictor currently available. A recent large genome‐wide association study reported associations between variation in the GLP1R drug‐target gene and both weight‐loss efficacy and gastrointestinal tolerability, and between agent‐specific GIPR variants and nausea and vomiting with tirzepatide; these self‐reported, single‐cohort and as‐yet unreplicated findings remain hypothesis‐generating rather than a basis for individual‐level genotyping. Metabolic, microbiome and neuroendocrine predictors are at a comparably preliminary stage. Conclusion No single baseline characteristic reliably predicts response. Structured assessment of early on‐treatment response is currently the most defensible basis for individualising therapy; genetic, metabolic and microbiome markers require prospective replication before clinical application.
EUVIMED